During trading hours on the 9th, domestic bio and pharmaceutical-related stocks rallied across the board. As global pharmaceutical companies intensify their competition to develop treatments for neurodegenerative diseases, expectations for the research and development outcomes of domestic bio companies have grown, drawing buying interest into related stocks.

As of the morning session, ABL Bio was traded at 84,800 won, up 4.05% from the previous trading day. GemVax rose 3.31% to 11,230 won, while HLB Pharmaceutical climbed 2.43% to 11,810 won. Hyundai Pharmaceutical gained 4.86% to 4,750 won, and PeptroN was traded at 162,500 won, up 1.31%, as dementia-related stocks broadly showed an upward trend. In addition, Nature Cell rose 2.76%, People Bio 2.90%, Quracle 3.05%, Oscotec 1.74%, and Dong-A ST 1.70%, as buying spread throughout the bio and pharmaceutical sector.

In the market, expectations are growing that the dementia treatment market will establish itself as a long-term growth industry as the population ages rapidly. In particular, the competition to develop treatments for degenerative brain diseases, including Alzheimer's disease, has emerged as a key area in the global pharmaceutical industry, drawing attention to the R&D achievements of domestic companies.

Meanwhile, the U.S. stock market closed mixed overnight as tensions between the U.S. and Iran flared up again, but investment sentiment toward growth industries such as bio and AI remained relatively robust. This is interpreted as a factor driving buying interest into high-growth bio stocks in the domestic market as well.

However, some analysts note that since the development of dementia treatments involves clinical trial results and regulatory approvals that significantly impact corporate value, it is necessary to comprehensively review R&D progress, technology exports, and earnings performance rather than focusing solely on short-term stock price movements.

[This article was written with the assistance of AI and is based on publicly available data and market information. Some information may change over time, so please be sure to verify official materials, including disclosures from the Korea Exchange and corporate filings, before making investment decisions. This article is not intended to recommend the purchase or sale of any specific stock or to solicit investment, and the final investment decision and responsibility lie with the reader.]